Publications

Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet J-P, Ahmann GJ, Adli M, Anderson KC, Ardlie K, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Initial genome sequencing and analysis of multiple myeloma. Nature 471(7339):467-472 (2011)   PMID: 21430775

Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng W-J, Van Wier S, Tiedemann R, Shi C-X, Sebag M, Braggio E, Henry T, Zhu Y-X, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL. Promiscuous Mutations Activate the Non-Canonical NF-kB Pathway in Multiple Myeloma. Cancer Cell 12(1):131-144 (2007) PMID: 17692805

Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten Years and Counting: So what do we know about t(4;14)(p16q;32) Multiple Myeloma. Leukemia and Lymphoma 47(11):2289-3000 (2006) PMID: 17107900

Keats JJ, Maxwell CA, Taylor BJ, Chesi C, Bergsagel PL, Larratt LM, Mant MJ, Reiman T, Belch AR, Pilarski LM. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32) positive multiple myeloma patients.  Blood 105(10):4060-4069 (2005) PMID: 15677557

Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM.  In Multiple Myeloma, t(4;14)(p16;q35) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101(4):1520-1529 (2003) PMID: 12393535